Avelumab and Merkel Cell Carcinoma: Understanding the Relationship

From General Health to Exposure-Specific Risk

For decades, public health communication has centered on general wellness principles, emphasizing lifestyle factors such as diet, exercise, and routine screenings to mitigate disease risk. This broad foundation has served as the primary lens through which health information is disseminated, often focusing on population-level behaviors rather than specific clinical exposures. Within this legacy framework, discussions of cancer risk have typically revolved around modifiable behaviors and environmental factors, leaving little room for the nuanced role of pharmaceutical interventions in disease causation. As medical science advances, however, the boundaries of this general health paradigm are increasingly tested by targeted therapies and their unintended consequences. One such area of emerging concern involves the relationship between immunotherapeutic agents and subsequent oncological outcomes. Specifically, the administration of Avelumab—a programmed death-ligand 1 blocking antibody—has prompted scrutiny regarding its potential association with Merkel cell carcinoma development. This shifts the focus from broad health maintenance to a more precise occupational and clinical exposure context. The pivot from general health education to exposure-specific risk assessment requires acknowledging that certain therapeutic compounds may, under specific conditions, contribute to carcinogenic processes. This transition does not imply causation but rather opens a necessary dialogue about monitoring and surveillance in populations receiving such treatments. By moving beyond generic health advice, we can better address the complexities inherent in modern pharmacotherapy and its long-term implications.

Avelumab as a Treatment for Merkel Cell Carcinoma

Avelumab (Bavencio®) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It is approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with a poor prognosis (https://pubmed.ncbi.nlm.nih.gov/29799096/). Approval was based on the JAVELIN Merkel 200 phase II trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). Avelumab is the first therapeutic agent specifically approved for this indication and is approved independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). Merkel cell carcinoma is a highly aggressive skin cancer with neuroendocrine differentiation, associated with chronic ultraviolet light exposure and the Merkel cell polyoma virus (https://pubmed.ncbi.nlm.nih.gov/35877101/). The incidence of MCC is increasing, and it is associated with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors, including avelumab, have significantly improved treatment outcomes in metastatic disease, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). However, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). The causal relationship between avelumab and Merkel cell carcinoma is not one of induction; rather, avelumab is a treatment for MCC. The evidence does not indicate that avelumab causes MCC. Instead, avelumab is used to treat existing MCC, and the primary concern is its efficacy and safety in this patient population.

Management of Avelumab-Refractory Merkel Cell Carcinoma

For patients who are refractory to avelumab, treatment options are limited. In a multicenter study of the prospective skin cancer registry ADOREG, ipilimumab plus nivolumab was evaluated in avelumab-refractory MCC patients (https://pubmed.ncbi.nlm.nih.gov/36450381/). Similarly, a retrospective study examined ipilimumab plus nivolumab in anti-PD-L1/PD-1 refractory MCC (https://pubmed.ncbi.nlm.nih.gov/35877101/). In a separate report, three out of five patients with avelumab-refractory metastatic MCC responded to combined ipilimumab and nivolumab according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/). Regarding adverse effects, checkpoint inhibitors including avelumab are known to cause overactivation of the immune system, leading to immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). One reported case described hypercalcemia secondary to reactivation of sarcoidosis in a patient with metastatic MCC on avelumab; the hypercalcemia was managed with corticosteroids to full resolution, and avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781/). This case illustrates that while avelumab can trigger immune-related complications, these are manageable and do not necessarily require treatment discontinuation.

Risk Considerations and Causation Analysis

Risk considerations for affected patients include the adequacy of warnings regarding avelumab and MCC. The evidence indicates that avelumab is approved specifically for MCC, and its prescribing information includes warnings about immune-related adverse events. However, the evidence does not suggest that avelumab causes MCC; rather, it is a treatment for the disease. Causation-related considerations for patients focus on the timeline between exposure to avelumab and documented harm. In the case of immune-related adverse events, such as sarcoidosis reactivation, the harm occurred during treatment and was managed without cessation of therapy (https://pubmed.ncbi.nlm.nih.gov/31543781/). For patients who are refractory to avelumab, the timeline between exposure and lack of response is variable, and subsequent treatment options like ipilimumab plus nivolumab may be considered (https://pubmed.ncbi.nlm.nih.gov/33439294/). In summary, avelumab is an effective treatment for metastatic MCC, with a well-characterized safety profile that includes immune-related adverse events. The evidence does not support a causal link between avelumab and the development of MCC; instead, avelumab is used to treat the disease. Patients who are refractory to avelumab have limited but emerging options, such as combination immunotherapy. The risk narrative should emphasize that avelumab is a therapeutic agent for MCC, not a cause of the disease, and that adverse events are manageable with appropriate medical intervention.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Does avelumab cause Merkel cell carcinoma?

No, the evidence does not indicate that avelumab causes Merkel cell carcinoma. Avelumab is a treatment for existing Merkel cell carcinoma, not a cause of the disease. It is an immune checkpoint inhibitor approved for metastatic Merkel cell carcinoma.

What are the risks of avelumab treatment?

Avelumab can cause immune-related adverse events due to overactivation of the immune system, such as sarcoidosis reactivation. These are generally manageable with corticosteroids and do not always require treatment discontinuation (https://pubmed.ncbi.nlm.nih.gov/31543781/).

What options are available if avelumab stops working?

For patients refractory to avelumab, combination immunotherapy with ipilimumab and nivolumab has shown promise in some studies (https://pubmed.ncbi.nlm.nih.gov/33439294/, https://pubmed.ncbi.nlm.nih.gov/36450381/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel cell carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.